Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease

References

• VestboJ, EdwardsLD, ScanlonPD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192. doi:10.1056/NEJMoa110548221991892
   PubMed Web of Science ®Google Scholar
• HalpinDMG, DecramerM, CelliBR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85–91. doi:10.1016/j.rmed.2017.04.01328610675
   PubMed Web of Science ®Google Scholar
• TashkinDP, LiN, HalpinD, et al. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med. 2013;107(12):1904–1911. doi:10.1016/j.rmed.2013.08.00123972968
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AndersonJA, BrookRD, et al. Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. Am J Respir Crit Care Med. 2018;197(1):47–55. doi:10.1164/rccm.201610-2086OC28737971
   PubMed Web of Science ®Google Scholar
• BurgePS, CalverleyPM, JonesPW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J. 2000;320(7245):1297–1303. doi:10.1136/bmj.320.7245.129710807619
   PubMed Web of Science ®Google Scholar
• PahusL, BurgelP-R, RocheN, et al. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm Med. 2019;19(1):127. doi:10.1186/s12890-019-0882-y31299936
   PubMed Web of Science ®Google Scholar
• CasanovaC, de TorresJP, Aguirre-JaímeA, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184(9):1015–1021. doi:10.1164/rccm.201105-0831OC21836135
   PubMed Web of Science ®Google Scholar
• Pérez-PadillaR, Fernandez-PlataR, Montes de OcaM, et al. Lung function decline in subjects with and without COPD in a population-based cohort in Latin-America. PLoS One. 2017;12(5):e0177032–e0177032. doi:10.1371/journal.pone.017703228472184
   PubMed Web of Science ®Google Scholar
• KimSJ, LeeJ, ParkYS, et al. Age-related annual decline of lung function in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;11:51–60. doi:10.2147/COPD.S9502826766907
   PubMed Web of Science ®Google Scholar
• DransfieldMT, KunisakiKM, StrandMJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324–330.27556408
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• CalverleyPM, AndersonJA, BrookRD, et al. Fluticasone furoate, vilanterol and lung function decline in patients with moderate COPD and heightened cardiovascular risk. Am J Respir Crit Care Med. 2017;197(1):47–55.
   Web of Science ®Google Scholar
• CalverleyPMA, SpencerS, WillitsL, et al. Withdrawal from treatment as an outcome in the ISOLDE Study of COPD. Chest. 2003;124(4):1350–1356. doi:10.1378/chest.124.4.135014555565
   PubMed Web of Science ®Google Scholar
• PauwelsRA, LöfdahlC-G, LaitinenLA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1948–1953. doi:10.1056/NEJM19990624340250310379018
   PubMed Web of Science ®Google Scholar
• AbramsonMJ, KaushikS, BenkeG, et al. Symptoms and lung function decline in a middle-aged cohort of males and females in Australia. Int J Chron Obstruct Pulmon Dis. 2016;11:1097–1103. doi:10.2147/COPD.S10381727307725
   PubMed Web of Science ®Google Scholar
• KimJ, YoonHI, OhY-M, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–1827. doi:10.2147/COPD.S8776626379432
   PubMed Web of Science ®Google Scholar
• SilvestreOM, NadruzW, Querejeta RocaG, et al. Declining lung function and cardiovascular risk: the ARIC Study. J Am Coll Cardiol. 2018;72(10):1109–1122. doi:10.1016/j.jacc.2018.06.04930165982
   PubMed Web of Science ®Google Scholar
• SakhamuriS, LutchmansinghF, SimeonD, et al. Reduced forced vital capacity is independently associated with ethnicity, metabolic factors and respiratory symptoms in a Caribbean population: a cross-sectional study. BMC Pulm Med. 2019;19(1):62. doi:10.1186/s12890-019-0823-930866890
   PubMed Web of Science ®Google Scholar
• LuotoJ, PihlsgårdM, WollmerP, et al. Relative and absolute lung function change in a general population aged 60–102 years. Eur Respir J. 2019;53(3):3. doi:10.1183/13993003.01812-2017
   Web of Science ®Google Scholar
• TriebnerK, MatulongaB, JohannessenA, et al. Menopause is associated with accelerated lung function decline. Am J Respir Crit Care Med. 2017;195(8):1058–1065. doi:10.1164/rccm.201605-0968OC27907454
   PubMed Web of Science ®Google Scholar
• GriffithKA, SherrillD, SiegelE, et al. Predictors of loss of lung function in the elderly: the Cardiovascular Health Study. Am J Respir Crit Care Med. 2001;163(1):61–68. doi:10.1164/ajrccm.163.1.990608911208627
   PubMed Web of Science ®Google Scholar
• Garcia-AymerichJ, LangeP, BenetM, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(5):458–463. doi:10.1164/rccm.200607-896OC17158282
   PubMed Web of Science ®Google Scholar
• HerrettE, GallagherAM, BhaskaranK, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.26050254
   PubMed Web of Science ®Google Scholar
• QuintJK, MullerovaH, DiSantostefanoRL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• BookerR. Vital Lung Function: Your Essential Reference on Lung Functional Testing. London: Class Health; 2008.
   Google Scholar
• RothnieKJ, MüllerováH, SmeethL, et al. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice–based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC29474094
   PubMed Web of Science ®Google Scholar
• NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management | guidance and guidelines. Available from: https://www.nice.org.uk/guidance/cg101. Accessed 1112, 2020.
   Google Scholar
• RothnieKJ, ChandanJ, GossH, et al. Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. Int J Chron Obstruct Pulmon Dis. 2017;12:1663–1668. doi:10.2147/COPD.S13389128652719
   PubMed Web of Science ®Google Scholar
• KestenS, CelliB, DecramerM, et al. Adverse health consequences in COPD patients with rapid decline in FEV1 – evidence from the UPLIFT trial. Respir Res. 2011;12(1):129. doi:10.1186/1465-9921-12-12921955733
   PubMed Web of Science ®Google Scholar
• ManninoDM, DavisKJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61(6):472–477. doi:10.1136/thx.2005.05244916517577
   PubMed Web of Science ®Google Scholar
• ChienJW, AuDH, BarnettMJ, et al. Spirometry, rapid FEV 1 decline, and lung cancer among asbestos exposed heavy smokers. COPD. 2007;4(4):339–346. doi:10.1080/1541255070160134018027161
   PubMedGoogle Scholar
• YohannesAM, TampubolonG. Changes in lung function in older people from the English longitudinal study of ageing. Expert Rev Respir Med. 2014;8(4):515–521. doi:10.1586/17476348.2014.91922624832442
   PubMed Web of Science ®Google Scholar
• SuzukiM, MakitaH, KonnoS, et al. Annual change in FEV1 in elderly 10-year survivors with established chronic obstructive pulmonary disease. Sci Rep. 2019;9(1):2073. doi:10.1038/s41598-019-38659-830765818
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, BrookRD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• LeeHY, ChoiSM, LeeJ, et al. Effect of tiotropium on lung function decline in early-stage of chronic obstructive pulmonary disease patients: propensity score-matched analysis of real-world data. Int J Chron Obstruct Pulmon Dis. 2015;10:2185–2192.26508848
   PubMed Web of Science ®Google Scholar
• FletcherC, PetoR. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648. doi:10.1136/bmj.1.6077.1645871704
   PubMed Web of Science ®Google Scholar
• AnthonisenNR, ConnettJE, MurrayRP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675–679. doi:10.1164/rccm.211209612204864
   PubMed Web of Science ®Google Scholar
• TashkinDP, GoodinT, BowlingA, et al. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. Respir Res. 2019;20(1):135. doi:10.1186/s12931-019-1112-031266489
   PubMed Web of Science ®Google Scholar
• BosséR, SparrowD, RoseCL, WeissST. Longitudinal effect of age and smoking cessation on pulmonary function. Am Rev Respir Dis. 1981;123(4):378–381.7224350
   PubMed Web of Science ®Google Scholar
• CelliBR, ThomasNE, AndersonJA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(4):332–338. doi:10.1164/rccm.200712-1869OC18511702
   PubMed Web of Science ®Google Scholar
• BecklakeMR, KauffmannF. Gender differences in airway behaviour over the human life span. Thorax. 1999;54(12):1119–1138. doi:10.1136/thx.54.12.111910567633
   PubMed Web of Science ®Google Scholar
• KannerRE, ConnettJE, AltoseMD, et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med. 1994;150(4):956–961. doi:10.1164/ajrccm.150.4.79214697921469
   PubMed Web of Science ®Google Scholar
• DransfieldMT, WashkoGR, ForemanMG, et al. Gender differences in the severity of CT emphysema in COPD. Chest. 2007;132(2):464–470. doi:10.1378/chest.07-086317573503
   PubMed Web of Science ®Google Scholar
• BestallJC, PaulEA, GarrodR, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581. doi:10.1136/thx.54.7.58110377201
   PubMed Web of Science ®Google Scholar
• NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2018 [cited March 15, 2018]; Available from: https://www.nice.org.uk/guidance/ng115. Accessed 1112, 2020.
   Google Scholar
• TantucciC, ModinaD. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99. doi:10.2147/COPD.S2748022371650
   PubMed Web of Science ®Google Scholar
• JankowichMD, RoundsSIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141(1):222–231. doi:10.1378/chest.11-106222215830
   PubMed Web of Science ®Google Scholar
• BurneyPG, HooperR. Forced vital capacity, airway obstruction and survival in a general population sample from the USA. Thorax. 2011;66(1):49–54.20980245
   PubMed Web of Science ®Google Scholar
• ManninoDM, BuistAS, PettyTL, EnrightPL, ReddSC. Lung function and mortality in the United States: data from the first national health and nutrition examination survey follow up study. Thorax. 2003;58(5):388. doi:10.1136/thorax.58.5.38812728157
   PubMed Web of Science ®Google Scholar
• KoskelaJ, KatajistoM, KallioA, et al. Individual FEV 1 trajectories can be identified from a COPD cohort. COPD. 2016;13(4):425–430. doi:10.3109/15412555.2015.104342326807738
   PubMedGoogle Scholar
• LohCH, GeneseFA, KannanKK, et al. Spirometry in hospitalized patients with acute exacerbation of COPD accurately predicts post discharge airflow obstruction. Chronic Obstr Pulm Dis. 2018;5(2):124–133. doi:10.15326/jcopdf.5.2.2017.016930374450
   PubMed Web of Science ®Google Scholar
• SeemungalTAR, DonaldsonG, BhowmikA, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613. doi:10.1164/ajrccm.161.5.990802210806163
   PubMed Web of Science ®Google Scholar
• SunY, MilneS, JawJE, et al. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res. 2019;20(1):236. doi:10.1186/s12931-019-1209-531665000
   PubMed Web of Science ®Google Scholar
• BottaiM, PistelliF, Di PedeF, et al. Longitudinal changes of body mass index, spirometry and diffusion in a general population. Eur Respir J. 2002;20(3):665. doi:10.1183/09031936.02.0128200112358345
   PubMed Web of Science ®Google Scholar
• ChenY, HorneSL, DosmanJA. Body weight and weight gain related to pulmonary function decline in adults: a six year follow up study. Thorax. 1993;48(4):375. doi:10.1136/thx.48.4.3758511735
   PubMed Web of Science ®Google Scholar
• LahousseL, SeysLJM, JoosGF, et al. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50(2):1602470. doi:10.1183/13993003.02470-201628798087
   PubMed Web of Science ®Google Scholar
• AllinsonJP, HardyR, DonaldsonGC, et al. The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med. 2016;193(6):662–672. doi:10.1164/rccm.201511-2210OC26695373
   PubMed Web of Science ®Google Scholar
• JohannessenA, EaganTML, OmenaasER, et al. Socioeconomic risk factors for lung function decline in a general population. Eur Respir J. 2010;36(3):480–487. doi:10.1183/09031936.0018650920150201
   PubMed Web of Science ®Google Scholar
• HegewaldMJ, CrapoRO. Socioeconomic status and lung function. Chest. 2007;132(5):1608–1614. doi:10.1378/chest.07-140517998360
   PubMed Web of Science ®Google Scholar
• JacksonB, KubzanskyLD, CohenS, WeissS, WrightRJ. A matter of life and breath: childhood socioeconomic status is related to young adult pulmonary function in the CARDIA study. Int J Epidemiol. 2004;33(2):271–278. doi:10.1093/ije/dyh00315082626
   PubMed Web of Science ®Google Scholar
• FortisSA-O, et al., Combined forced expiratory volume in 1 second and forced vital capacity bronchodilator response, exacerbations, and mortality in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2019 ;16(7):826–835.30908927
   PubMed Web of Science ®Google Scholar
• NissenF, MoralesDR, MullerovaH, et al. Concomitant diagnosis of asthma and COPD: a quantitative study in UK primary care. Br J Gen Pract. 2018;68(676):e775–e782. doi:10.3399/bjgp18X69938930249612
   PubMed Web of Science ®Google Scholar
• ElbehairyAF, WhittakerH, QuintJK, et al. S49 Identifying patient suitability for lung volume reduction – estimation of gas trapping from spirometry. Thorax. 2018;73(Suppl 4):A30.
   Google Scholar